Your browser does not support JavaScript capabilities, which maybe required to display this page properly.


PDF FormatRequires Adobe Acrobat Reader

Table 6.6a

Immunosuppression Use for Induction, 1999 to 2008

Recipients with Pancreas Transplant Alone (PTA) Transplants

  Year of Transplant
1999 2000 2001 2002 2003 2004 2005 2006 2007 2008
Transplants 139 134 168 181 160 183 199 173 208 223
With Immunosuppression Info 136 128 165 178 155 179 193 167 200 219
Induction Drugs 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
ALG
Atgam/NRATG/NRATS 8.1% 0.0% 0.0% 0.0% 1.3% 2.2% 0.0% 0.6% 1.0% 1.4%
OKT3 7.4% 4.7% 3.0% 3.4% 0.6% 0.0% 2.1% 5.4% 7.5% 6.4%
Thymoglobulin 30.1% 48.4% 49.1% 60.1% 45.2% 50.3% 48.2% 41.9% 41.5% 49.8%
Zenapax 30.1% 44.5% 34.5% 30.9% 8.4% 9.5% 5.2% 10.8% 7.0% 6.8%
Simulect 11.0% 9.4% 3.0% 3.9% 6.5% 0.0% 2.1% 2.4% 3.5% 4.6%
Campath 0.0% 0.0% 0.0% 1.1% 31.6% 41.3% 33.7% 24.0% 14.0% 11.4%
No Induction Drugs Recorded 37.5% 29.7% 38.8% 30.3% 18.1% 20.1% 16.6% 21.0% 33.5% 26.9%


Source: OPTN/SRTR Data as of May 4, 2009.

Induction drugs include any reported antilymphocyte antibodies and antibodies directed against lymphocyte receptors.



PDF FormatRequires Adobe Acrobat Reader